Last reviewed · How we verify
MANP
At a glance
| Generic name | MANP |
|---|---|
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Enhancing the Natriuretic Peptide System in HFpEF (PHASE1, PHASE2)
- To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension (PHASE2)
- MANP in African Americans With Hypertension (PHASE1)
- Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects (PHASE1)
- MANP in Hypertension and Metabolic Syndrome (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MANP CI brief — competitive landscape report
- MANP updates RSS · CI watch RSS
- Mayo Clinic portfolio CI